Advertisement

Inflammation Research

, Volume 54, Issue 6, pp 235–242 | Cite as

Central administration of perfluorooctanoic acid inhibits cutaneous inflammation

  • B. K. Taylor
  • C. Kriedt
  • S. Nagalingam
  • N. Dadia
  • M. BadrEmail author
Original Research Paper

Abstract.

Objective: To elucidate the site of action of perfluorooctanoic acid (PFOA) in the carrageenan model of peripheral inflammation.

Subjects: Male Sprague-Dawley rats.

Treatment: We first compared the anti-edema effects of systemic PFOA (50–150 mg/kg) with prototypical nonsteroidal (acetylsalicylic acid, ASA, 50–200 mg/kg) and steroidal (dexamethasone, 0.5–5.0 mg/kg) drugs after the intraplantar injection of carrageenan (1%). We then compared the anti-edema effects of systemic PFOA with local intraplantar (10 mg/kg), and intracerebroventricular (i.c.v., 0.1–50 μg) routes of administration.

Results: Systemic PFOA was at least as or more efficacious than ASA or dexamethasone in reducing carrageenan-induced edema. RU-486 did not change the anti-edema effect of PFOA, ruling out a contribution of endogenous release of glucorticoids. I. c. v. PFOA, but not perfluorooctanes, dramatically reduced multiple signs of inflammation at doses well below the systemically-effective dose. We conclude that the anti-edema effect of high systemic doses of PFOA (≥100 mg/kg, i. p.) is mediated in part by actions in the brain.

Key words.

Carrageenan PFOA Aspirin Dexamethasone Nuclear hormone receptor Brain 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Birkhäuser Verlag, Basel 2005

Authors and Affiliations

  • B. K. Taylor
    • 1
  • C. Kriedt
    • 1
  • S. Nagalingam
    • 1
  • N. Dadia
    • 2
  • M. Badr
    • 2
    Email author
  1. 1.Department of PharmacologyTulane University Health Sciences CenterNew OrleansUSA
  2. 2.Division of Pharmacology, School of PharmacyUniversity of Missouri-Kansas CityKansas CityUSA

Personalised recommendations